Isabel Calvo

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Mafalda Oliveira, Cristina Saura, Paolo Nucíforo et al. · Annals of Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Pharmacology +13

Whole-Exome Sequencing Reveals Defective <i>CYP3A4</i> Variants Predictive of Paclitaxel Dose-Limiting Neuropathy

María Apellániz-Ruiz, Miyoung Lee, Lara M. Munín Sánchez et al. · Clinical Cancer Research · 2014 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Zhen Shi, Julia Wulfkuhle, Małgorzata Nowicka et al. · Clinical Cancer Research · 2021 · 54 citations · Full text

Medicine, Molecular Biology, Oncology +17

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

Miguel Quintela-Fandiño, Aňa Lluch, Luís Manso et al. · Clinical Cancer Research · 2016 · 41 citations

Medicine, Nuclear Medicine, Oncology +16

Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy

Lara M. Munín Sánchez, María Apellániz-Ruiz, Gerardo Gutiérrez‐Gutiérrez et al. · The Oncologist · 2018 · 37 citations · Full text

Medicine, Oncology, Pharmacology +17